Skip to main content
Top
Published in: BMC Infectious Diseases 1/2015

Open Access 01-12-2015 | Case report

Therapeutic drug monitoring and the conservative management of chronic tuberculous empyema: case report and review of the literature

Authors: Richard Long, James Barrie, Charles A. Peloquin

Published in: BMC Infectious Diseases | Issue 1/2015

Login to get access

Abstract

Background

Chronic tuberculous empyema (CTE) is a rare and unusual, low grade and protracted, infection of the pleural space resulting in marked thickening, even calcification of the visceral and parietal pleura. Historically its management has been extraordinarily challenging. Differential penetration of anti-TB drugs into the pleural space has resulted in acquired drug resistance and surgery to remove the empyema or close a complicating bronchopleural fistula (BPF) has been technically difficult or unacceptably hazardous. On the basis of limited experience, the combination of tube thoracostomy or catheter drainage and high-end dosing of anti-TB drugs has been recommended as an initial approach to these lesions. Herein we report the first well documented case of closure of a BPF and cure of a CTE using this approach. The chances of a favorable outcome are improved, we suggest, by using therapeutic drug monitoring (TDM) to guide high-end drug dosing.

Case Presentation

An 84 year old male immigrant to Canada from Croatia was diagnosed with a CTE after he developed a BPF. The diagnosis was made 62 years after what was, in retrospect, an episode of tuberculous pleurisy. He was treated with computed tomography-guided catheter drainage and TDM-guided high-end dosed anti-TB drugs (serum and pleural fluid drug concentrations) over a 10 month period. Sustained closure of the BPF and mycobacteriologic cure of the CTE was achieved. Drug concentrations in the present case and all other reported cases are summarized and interpreted.

Conclusion

When serum concentrations of the anti-TB drugs isoniazid, pyrazinamide and ethambutol at the high end of the normal range are achieved, pleural fluid concentrations at the low end of the normal range may be anticipated in CTE. Though highly protein bound drugs such as rifampin and moxifloxacin appear to penetrate CTEs less well, their free concentrations in the pleural space may be proportionately higher on account of lower protein concentrations. Interventional radiology and TDM increase the chances that conservative management of CTE will be successful.
Literature
1.
go back to reference Jenssen AD. Chronic calcified pleural empyema. Scand J Respir Dis. 1969;50:19–27.PubMed Jenssen AD. Chronic calcified pleural empyema. Scand J Respir Dis. 1969;50:19–27.PubMed
2.
go back to reference Sahn SA, Iseman MD. Tuberculous empyema. Sem Respir Infect. 1999;14:82–7. Sahn SA, Iseman MD. Tuberculous empyema. Sem Respir Infect. 1999;14:82–7.
3.
go back to reference Light RW. Tuberculous Pleural Effusions. In: Light RW, editor. Pleural Diseases. 6th ed. New York, NY: Lippincott Williams & Wilkins; 2013. p. 247–62. Light RW. Tuberculous Pleural Effusions. In: Light RW, editor. Pleural Diseases. 6th ed. New York, NY: Lippincott Williams & Wilkins; 2013. p. 247–62.
4.
go back to reference Roper WH, Waring JJ. Primary serofibrinous pleural effusion in military personnel. Am Rev Respir Dis. 1955;71:616–34. Roper WH, Waring JJ. Primary serofibrinous pleural effusion in military personnel. Am Rev Respir Dis. 1955;71:616–34.
5.
go back to reference Han DH, Song JW, Chung HS. Resolution of residual pleural disease according to time course in tuberculous pleurisy during and after the termination of antituberculosis medication. Chest. 2005;128:3240–5.CrossRefPubMed Han DH, Song JW, Chung HS. Resolution of residual pleural disease according to time course in tuberculous pleurisy during and after the termination of antituberculosis medication. Chest. 2005;128:3240–5.CrossRefPubMed
6.
go back to reference Iseman MD, Madsen LA. Chronic tuberculous empyema with bronchopleural fistula resulting in treatment failure and progressive drug resistance. Chest. 1991;100:124–7.CrossRefPubMed Iseman MD, Madsen LA. Chronic tuberculous empyema with bronchopleural fistula resulting in treatment failure and progressive drug resistance. Chest. 1991;100:124–7.CrossRefPubMed
7.
go back to reference Elliot AM, Berning SE, Iseman MD, Peloquin CA. Failure of drug penetration and acquisition of drug resistance in chronic tuberculous empyema. Tubercle Lung Dis. 1995;76:463–7.CrossRef Elliot AM, Berning SE, Iseman MD, Peloquin CA. Failure of drug penetration and acquisition of drug resistance in chronic tuberculous empyema. Tubercle Lung Dis. 1995;76:463–7.CrossRef
8.
go back to reference Peloquin CA. Antituberculosis Drugs: Pharmacokinetics. In: Heifets LB, editor. Drug susceptibility in the chemotherapy of mycobacterial infections. Boca Raton, FL: CRC Press; 1991. p. 59–88. Peloquin CA. Antituberculosis Drugs: Pharmacokinetics. In: Heifets LB, editor. Drug susceptibility in the chemotherapy of mycobacterial infections. Boca Raton, FL: CRC Press; 1991. p. 59–88.
9.
go back to reference Budha NR, Lee RE, Meibohm B. Biopharmaceutics, pharmacokinetics, and pharmacodynamics of antituberculosis drugs. Curr Medicinal Chem. 2008;15:809–25.CrossRef Budha NR, Lee RE, Meibohm B. Biopharmaceutics, pharmacokinetics, and pharmacodynamics of antituberculosis drugs. Curr Medicinal Chem. 2008;15:809–25.CrossRef
10.
go back to reference Peloquin CA, Hadad DJ, Molina LPD, et al. Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis. Antimicrob Agents Chemother. 2008;52:852–7.CrossRefPubMed Peloquin CA, Hadad DJ, Molina LPD, et al. Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis. Antimicrob Agents Chemother. 2008;52:852–7.CrossRefPubMed
11.
go back to reference Gumbo T. New susceptibility breakpoints for first-line antituberculosis drugs based on antimicrobial pharmacokinetic/pharmacodynamic science and population pharmacokinetic variability. Antimicrob Agents Chemother. 2010;54:1481–91.CrossRef Gumbo T. New susceptibility breakpoints for first-line antituberculosis drugs based on antimicrobial pharmacokinetic/pharmacodynamic science and population pharmacokinetic variability. Antimicrob Agents Chemother. 2010;54:1481–91.CrossRef
12.
go back to reference Long R, Barrie J, Stewart K, Peloquin C. Treatment of tuberculous empyema with simultaneous oral and intrapleural antituberculosis drugs. Can Respir J. 2008;15:241–3.CrossRefPubMedPubMedCentral Long R, Barrie J, Stewart K, Peloquin C. Treatment of tuberculous empyema with simultaneous oral and intrapleural antituberculosis drugs. Can Respir J. 2008;15:241–3.CrossRefPubMedPubMedCentral
13.
go back to reference Reeve PA, Seaton D. Tuberculous empyema – a case history extending over 30 years. Tubercle. 1986;67:147–50.CrossRefPubMed Reeve PA, Seaton D. Tuberculous empyema – a case history extending over 30 years. Tubercle. 1986;67:147–50.CrossRefPubMed
14.
go back to reference McDermott W, Tompsett R. Activation of pyrazinamide and nicotinamide in acidic environments in vitro. Am Rev Tuberc. 1954;70:748–54.PubMed McDermott W, Tompsett R. Activation of pyrazinamide and nicotinamide in acidic environments in vitro. Am Rev Tuberc. 1954;70:748–54.PubMed
15.
go back to reference Heifets L, Lindholm-Levy P. Pyrazinamide sterilizing activity in vitro against semi-dormant Mycobacterium tuberculosis bacterial populations. Am Rev Respir Dis. 1992;145:1223–5.CrossRefPubMed Heifets L, Lindholm-Levy P. Pyrazinamide sterilizing activity in vitro against semi-dormant Mycobacterium tuberculosis bacterial populations. Am Rev Respir Dis. 1992;145:1223–5.CrossRefPubMed
16.
go back to reference Mitchison DA. The action of antituberculosis drugs in short-course chemotherapy. Tubercle. 1985;66:219–25.CrossRefPubMed Mitchison DA. The action of antituberculosis drugs in short-course chemotherapy. Tubercle. 1985;66:219–25.CrossRefPubMed
17.
go back to reference Heifets LB. Antituberculosis drugs: antimicrobial activity in vitro. In: Heifets LB, editor. Drug susceptibility in the chemotherapy of mycobacterial infections. Boca Raton, FL: CRC Press; 1991. p. 13–57. Heifets LB. Antituberculosis drugs: antimicrobial activity in vitro. In: Heifets LB, editor. Drug susceptibility in the chemotherapy of mycobacterial infections. Boca Raton, FL: CRC Press; 1991. p. 13–57.
18.
go back to reference Neihart RE, Hof DG. Successful nonsurgical treatment of tuberculous empyema in an irreducible pleural space. Chest. 1985;88:792–4.CrossRefPubMed Neihart RE, Hof DG. Successful nonsurgical treatment of tuberculous empyema in an irreducible pleural space. Chest. 1985;88:792–4.CrossRefPubMed
19.
go back to reference Johnson TM, McCann W, Davey WN. Tuberculous bronchpleural fistula. Am Rev Respir Dis. 1973;107:30–41.PubMed Johnson TM, McCann W, Davey WN. Tuberculous bronchpleural fistula. Am Rev Respir Dis. 1973;107:30–41.PubMed
20.
go back to reference Haas AR, Sterman DH. Advances in pleural disease management including updated procedural coding. Chest. 2014;146:508–13.CrossRefPubMed Haas AR, Sterman DH. Advances in pleural disease management including updated procedural coding. Chest. 2014;146:508–13.CrossRefPubMed
21.
go back to reference Alsultan A, Peloquin CA. Therapeutic drug monitoring in the treatment of tuberculosis: an update. Drugs. 2014;74:839–54.CrossRefPubMed Alsultan A, Peloquin CA. Therapeutic drug monitoring in the treatment of tuberculosis: an update. Drugs. 2014;74:839–54.CrossRefPubMed
22.
Metadata
Title
Therapeutic drug monitoring and the conservative management of chronic tuberculous empyema: case report and review of the literature
Authors
Richard Long
James Barrie
Charles A. Peloquin
Publication date
01-12-2015
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2015
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-015-1093-7

Other articles of this Issue 1/2015

BMC Infectious Diseases 1/2015 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.